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Background. Parkinson’s disease (PD) and Alzheimer’s disease (AD) share pathological features, including amyloid-beta pathology.
Amyloid-beta peptide is generated by sequential proteolysis of amyloid precursor protein (APP), and genetic variations in the
processing pathway genes have been found to increase the risk of AD; however, the contribution in PD is unknown. Methods.
The aim of this study was to investigate whether candidate polymorphisms in five genes (ADAM10, BACE1, BACE2, PSEN2, and
CLU) involved in the APP processing pathway affect PD risk in a population-based cohort of patients with incident PD and control
subjects from the Norwegian ParkWest study. Results. We found an association of rs638405 in BACE1 with increased risk of PD,
thus providing a novel link, at the genetic level, between amyloid-beta pathology and PD.
1. Introduction
Parkinson’s disease (PD) and Alzheimer’s disease (AD) are
the two most common age-related neurodegenerative dis-
eases. PD is primarily a movement disorder, the charac-
teristic motor features of which mainly result from loss of
dopaminergic neurons in the substantia nigra pars compacta
[1]. However, patients with PD may experience a range of
nonmotor symptoms, including some features commonly
associated with AD, such as mild cognitive impairment that
frequently progresses to dementia [2]. In addition to Lewy
body pathology, typical AD related morphological changes,
including amyloid-beta (A𝛽) pathology, have been proposed
to be involved in the pathogenesis of PD dementia. This is
reinforced by neuroimaging studies using PET, and with the
strong inverse association between A𝛽 load at autopsy and
time to dementia in PD [3, 4].
A𝛽 peptides are formed by the cleavage of amyloid
precursor protein (APP), which can be processed by at
least three proteinases, termed 𝛼-, 𝛽-, and 𝛾-secretases, via
either amyloidogenic or nonamyloidogenic APP processing
pathways [5]. According to the amyloid cascade hypothesis,
an imbalance between A𝛽 production and clearance plays a
critical role in AD pathogenesis. Genetic variations in both
APP and the genes encoding enzymes of the APP processing
pathway are linked to modified risk of AD [6–8], elevated
APP production [6], and changes in CSF A𝛽 levels [9–11].
In light of the occurrence of A𝛽 pathology in PD, we sought
to determine if genetic variations within five genes involved
in APP processing and clearance (ADAM10, BACE1, BACE2,
PSEN2, and CLU1) are risk factors for PD in an unselected,
population-based cohort of patients with incident PD and
age-matched controls.
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2. Methods
2.1. Patients and Controls. All patients (𝑛 = 184, 60.9% male,
mean age at onset 68.1 years ± 9.2 SD) and normal controls
(𝑛 = 178, 51.4% male, mean age at inclusion 66.7 years ±
9.6 SD) participate in the ongoing Norwegian ParkWest
study [12]. ParkWest is a large population-based multicenter
study of newly diagnosed drug-na¨ıve PD patients designed
to determine the incidence, neurobiology, and prognosis
of PD. Multiple recruitment strategies were employed to
identify all patients with incident PD in four counties in
Southwestern Norway during a 22-month period between
the 1st of November 2004 and the 31st of August 2006 [12].
Patients underwent comprehensive and standardized clinical
examinations before drug treatment was initiated, including
rating of disease severity by Unified Parkinson’s Disease Rat-
ing Scale (UPDRS, baseline score 23.6 ± 11.2 SD) and Hoehn
and Yahr staging (baseline score 1.9 ± 0.6 SD). Diagnosis
of dementia was made according to the established criteria
[13], and by two study neurologists, as previously described
[14]. PD patients are currently under continued follow-up,
and only those whose diagnosis remained unchanged until
their latest clinical visit, on average 4.6 (1.1 SD) years after
first presentation, were considered eligible for this study to
maximize diagnostic accuracy [12]. During the same time
period, we also recruited normal control subjects in the same
geographical area. Controls being first- or second-degree
relatives of patients were disregarded for single nucleotide
polymorphism (SNP) genotype analysis (𝑛 = 10). All
participants signed written-informed consent. The Regional
Committee for Research Ethics of the University of Bergen,
Norway, approved the study.
2.2. Genetic Analyses. To investigate the role of genetic
variation in the APP processing genes in PD risk, we first
selected loci based on their biologically established role in the
APP processing pathway [5]. SNPs were further prioritized
if located in a known regulatory or coding region, and/or
associated with APP processing or with AD in previous stud-
ies (BACE [8, 15]; ADAM10 [9]; PSEN [10]; and CLU [16]).
Eight SNPs in 5 genes were selected: ADAM10 (rs514049,
rs2305421), BACE1 (rs638405, rs11601511), BACE2 (rs12149,
rs2252576), PSEN2 (rs1295652), and CLU (rs11136000). We
also included ApoE SNPs rs429358 and rs7412, which have
been previously linked to PD, AD, and amyloid plaque
burden [17–19].
Large-scale allelic discrimination analysis was performed
using predesigned TaqMan SNP genotyping assays (Applied
Biosystems). The amplification reactions were carried out
in an ABI PRISM 7300 Real Time PCR System. Postam-
plification allelic specific fluorescence was measured using
SequenceDetection System software.The call rate for all SNPs
was >99%.The concordance rate for replicate TaqMan assays
was 100%.
2.3. Statistical Analysis. Statistical analyses were computed
with the IBM SPSS Statistics 22 software (2013) and the web
based tool SNPStats [20]. Statistical significance of differences
in genotype and allele frequencies between the patient and
control group was assessed with Fisher’s exact test (SPSS
exact test module). Statistical significance of genotype asso-
ciations with the risk of either PD or diagnosis of dementia
within 5 years of follow-up, odds ratios, and 95% confidence
intervals were estimated by logistic regression with age and
sex included as covariates (SPSS). Statistical significance of
differences of continuous and categorical variables between
patient and control group was estimated using 𝑡-test (age
variables), ANCOVA with age and sex included as covariates
(continuous variables), or Fisher’s exact test (categorical
variables). Deviation from Hardy-Weinberg equilibrium was
tested using an exact test within the SNPStats tool (with 1
degree of freedom). A value of 𝑃 < 0.05 was considered
statistically significant for single comparisons and 𝑃 < 0.006
for multiple comparisons (𝑛 = 8).
3. Results
Blood samples from 184 patients and 178 controlswere subject
to analysis.The genotype frequencies in patients and controls
were in Hardy-Weinberg equilibrium (Table 1). Comparison
of genotype frequency between PD and controls showed that
theBACE1 SNP rs638405was significantly associatedwith PD
(Table 1). Risk of PD association was estimated using logistic
regression adjusting for covariates age and gender, showing
that the “C” allele conferred increased risk of PD (odds ratio
[OR]: 2.29; 95% confidence interval [CI]: 1.24–4.21; 𝑃 =
0.008; see Supplementary Table 1 in Supplementary Material
available online at http://dx.doi.org/10.1155/2015/973298). We
did not identify an association with rs514049, rs2305421,
rs11601511, rs12149, rs2252576, rs1295652, or rs11136000 and
risk of PD or clinical measures of PD severity at diagnosis
(Table 1 and data not shown).
TheBACE1 rs638405major allele has been associatedwith
increased risk for late-onset AD (LOAD), and several studies
have observed that this effect is enhanced in ApoE-𝜀4 carriers
[7, 8, 21, 22]. We tested for a possible link between rs638405
and ApoE-𝜀4 in our cohort and found that ApoE-𝜀4 did not
add to the effect of rs638405 on PD risk (data not shown).
Genetic factors that increase A𝛽 aggregation cause AD
and variants in BACE1 have also been associated with demen-
tia in Down’s syndrome [23]. Therefore, we analyzed the
possibility that rs638405 is associated with an increased risk
of dementia in patients with PD. Of the 184 patients with
PD included in this study, 35 were diagnosed with dementia
within five years of PD diagnosis. Risk of dementia in patients
with PD was estimated using logistic regression adjusting for
age and gender. We found no significant association between
the “C” allele of rs638405 and the early diagnosis of dementia
among the patients with PD ([OR]: 1.64; 95% CI: 0.43–6.29;
𝑃 = 0.471).
4. Discussion
This exploratory study shows that rs638405, a BACE1 SNP
previously associated with AD in both Caucasian [7, 8, 21]
and Asian populations [22, 24, 25], is also associated with
an increased risk of PD in the Norwegian ParkWest study
(Table 1). The link between BACE1 and PD is of clinical
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Table 1: Genotype and allele frequencies.
Gene SNP ID
Allele
m/M
𝑛
PD
𝑛
controls
Genotype frequencies (𝑛)
HWE 𝑃§Patients Controls 𝜒2 𝑃#
m/m m/M M/M m/m m/M M/M
ADAM10 rs514049 a/C 183 177 32 99 52 27 93 57 0.70 0.11
rs2305421 g/A 184 178 3 47 134 3 37 138 0.55 1.00
BACE1 rs638405 g/C 184 178 19 97 68 35 73 70 0.02 0.91
rs11601511 c/G 184 178 4 53 127 5 48 125 0.86 1.00
BACE2 rs12149 c/T 184 178 48 90 46 41 86 51 0.68 0.60
rs2252576 t/C 184 178 15 67 102 15 62 101 0.96 0.17
PSEN2 rs1295652 a/G 184 178 7 60 117 13 58 107 0.34 0.44
CLU rs11136000 t/C 184 177 28 88 68 23 82 72 0.72 1.00
MAF:minor allele frequency. HWE:Hardy-Weinberg equilibrium. #Two-tailedP value fromFisher’s exact test. §Exact test againstHardy-Weinberg distribution
(SNPStats).
importance because of the essential role of BACE1 in the
generation of toxic A𝛽 peptides [26], the observed A𝛽
pathology in PD [3, 4], and the recent association between
detectable changes in A𝛽 levels and clinical features of PD
[14, 27–29].
CSF A𝛽42 is emerging as an independent predictor of
progression to dementia in patients with PD and is gaining
increased attention in the field (reviewed in [30]). In this
study, we investigated the usefulness of rs638405 to discrim-
inate PD with dementia from PD without dementia and
found no associationwith the early development of dementia.
Research on genetic susceptibility to dementia in PDhas been
inconclusive; however, several studies have identified SNPs
that are associated with dementia in patients with a longer
disease course [30], and it will be interesting to reassess the
association of BACE1 SNPs with dementia in more advanced
PD.
PD and AD exist along a spectrum of neurodegenerative
disorders. The observed overlap in clinical and pathological
features has led to the hypothesis that AD and PD may share
some common genetic determinants. To investigate this,
several studies examined the effect of sporadic PD risk alleles
in AD (and vice versa) utilizing GWAS data [31, 32], but they
failed to identify loci that increase the risk of both PD and
AD. However, studies of targeted candidate SNPs have found
associations with both diseases and several loci, including
MAPT [33, 34], PON1 [35, 36], and TREM2 [37], suggesting
that some common genetic mechanisms may underlie the
pathology of PD and AD.
rs638405 has been repeatedly found to be associated with
an increased risk of AD [7, 8, 21, 22, 24, 25] and also with
an increased risk of the degenerative neurological disorder
sporadic Creutzfeldt-Jakob disease [38]. In light of this, we
suggest that although the level of association detected in this
study may be due to increased type I errors in multiple com-
parisons, the BACE1 rs638405 polymorphism is worthy of
further investigation in PD, as it provides both a novel genetic
link to the observed overlap in the amyloid pathology of PD
and AD and increases the number of neurodegenerative dis-
eases that this variant is associated with. As BACE1 rs638405
is a silent polymorphism, the mechanism of association with
disease is unclear. This is further complicated by the findings
that the genotype and allele frequencies vary among different
ethnic groups, and in different populations either the G allele
or the GG genotype [7, 8, 21, 24], or the C allele or CC
genotype [22, 25, 38], is associated with increased risk of
disease. Some have speculated that this SNPmay be in linkage
disequilibrium with other functional variant(s), either in the
BACE1 gene itself or in another gene nearby, which have not
yet been investigated.
In this study, we targeted our investigation of the genetic
overlap between PD and AD by focusing on candidate
genes that could contribute to the overlapping A𝛽 pathology.
Limitations of this study include the decision to test only
selected genes and SNPs relevant to APP processing and the
fact that the cohort size is limited, meaning that some genetic
contributions to APP processing and PD risk may have been
missed.
A similar approach was recently undertaken in a study
of 86 patients with PD and 161 controls, in which a panel
of genetic variants in APP processing genes was investigated
[39]. The authors did not find an association between BACE1
polymorphisms and PD compared to controls. However,
prior multiple comparison correction results showed an
association between APP processing genes and PD compared
to controls. Furthermore, the authors showed a significant
association between two SNPs inAPP (rs466448) andAPH1B
(rs2068143) and CSF A𝛽42 levels in patients with PD [39].
Taken together, this previous study and the results presented
here suggest that variants in APP processing pathway genes
may play a biological role in PD.
5. Conclusion
In summary, our results show that BACE1 rs638405 is asso-
ciated with an increased risk for developing PD, increasing
the spectrum of neurodegenerative diseases that this variant
plays a role in.These results, together with recently published
works showing that A𝛽 levels are altered in patients with PD
in both Norwegian ParkWest study [14, 27, 28] and other
4 Parkinson’s Disease
studies [29], suggest an interesting area of research, linking
common genetic risk factors with AD and overlapping
pathogenic mechanisms leading to altered APP processing.
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